Walvax Biotechnology Co., Ltd., based in China, is a pharmaceutical company with a focus on bio-medicine products, including vaccines and blood products. With a medium risk rating score of 26.9, Walvax Biotechnology Co Ltd is committed to research, development, production, and sales of ESG-friendly bio-medicines for a sustainable future. The company offers a range of innovative products, such as Haemophilus influenza type b conjugate vaccines and group A and C meningococcal polysaccharide vaccines.